The refinement of these highly selective therapeutic tools, either alone or combined with chemotherapeutic agents, TK inhibitors, or immune checkpoint inhibitors, will help treat cancer types driven by the c-KIT signaling machinery. The gene discussed is KIT; the disease is cancer.